How Heart Rate Should Be Controlled in Patients with Atherosclerosis and Heart Failure

Current Atherosclerosis Reports
Rose Mary Ferreira Lisboa da SilvaGiuseppe Biondi-Zoccai

Abstract

Resting heart rate is an independent risk factor for all-cause and cardiovascular mortality in patients with heart failure. The main objectives are to discuss the prognosis of heart rate, its association with coronary atherosclerosis, and the modalities of control of the heart rate in sinus rhythm and in the rhythm of atrial fibrillation in patients with chronic heart failure. As a therapeutic option for control heart rate, medications such as beta-blockers, digoxin, and finally ivabradine have been studied. Non-dihydropyridine calcium channel blockers are contraindicated in patients with heart failure and reduced ejection fraction. The influence of the magnitude of heart rate reduction and beta-blocker dose on morbidity and mortality will be discussed. Regarding the patients with heart failure and atrial fibrillation, there are different findings in heart rate control with the use of a beta-blocker. Patients eligible for ivabradine have clinical benefits and increased ejection fraction. Vagal nerve stimulation has low efficacy for the control of heart rate. Complementary therapies such as tai chi and yoga showed no effect on heart rate. In this review, we discuss the main therapeutic options for the control of heart rate in pa...Continue Reading

References

Jun 1, 1987·American Heart Journal·W B KannelL A Cupples
Dec 1, 1994·Journal of the American College of Cardiology·S M RyanL A Lipsitz
Sep 27, 2005·American Journal of Hypertension·Junko YamaguchiYutaka Imai
Jun 3, 2009·Annals of Internal Medicine·Finlay A McAlisterPaul W Armstrong
Nov 11, 2009·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Richard L Verrier, Alex Tan
Jul 6, 2010·The American Journal of Cardiology·Marcelo C ShibataBen Vandermeer
Aug 18, 2010·The Journal of General Physiology·H Peter Larsson
Apr 27, 2011·Nature Reviews. Cardiology·Kim M Fox, Roberto Ferrari
Jun 28, 2012·European Journal of Heart Failure·Roman PfisterKay-Tee Khaw
Sep 14, 2012·Heart Failure Reviews·Maya Guglin
Apr 20, 2013·Circulation. Heart Failure·David NanchenAbbas Dehghan
Nov 12, 2013·International Journal of Cardiology·Francisco J Pastor-PérezArcadio García-Alberola
Jan 15, 2014·Journal of the American College of Cardiology·Anders OpdahlJoão A C Lima
May 9, 2014·Journal of the American Heart Association·Jennifer E HoThomas J Wang
Sep 2, 2014·The New England Journal of Medicine·Kim FoxUNKNOWN SIGNIFY Investigators
Sep 7, 2014·Lancet·Dipak KotechaUNKNOWN Beta-Blockers in Heart Failure Collaborative Group
Oct 15, 2014·Nature Reviews. Cardiology·Paul Khairy, Denis Roy
Apr 17, 2015·International Journal of Cardiology·Da LongQiming Liu
Jun 11, 2015·Applied Psychophysiology and Biofeedback·Paul PosadzkiEdzard Ernst
Jul 15, 2015·The American Journal of Medicine·Gordon A Ewy
Sep 16, 2015·Journal of the American Heart Association·Benjamin A SteinbergUNKNOWN Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and Patients
Sep 19, 2015·Circulation·Tze-Fan ChaoShih-Ann Chen
Dec 20, 2015·JACC. Heart Failure·Frank EdelmannUNKNOWN CIBIS-ELD Investigators and Project Multicenter Trials in the Competence Network Heart Failure
Mar 12, 2016·Neuroscience and Biobehavioral Reviews·Julian Koenig, Julian F Thayer
May 10, 2016·Complementary Therapies in Clinical Practice·Aimee R ColeNipon Chattipakorn
Aug 4, 2016·Critical Care Nursing Clinics of North America·Shu-Fen Wung
Nov 4, 2016·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Paulus KirchhofKatja Zeppenfeld
Jan 10, 2017·European Heart Journal·Udo BavendiekJohann Bauersachs
Mar 31, 2017·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Csaba András Dézsi, Veronika Szentes
May 4, 2017·Journal of the American College of Cardiology·Dipak KotechaUNKNOWN Beta-Blockers in Heart Failure Collaborative Group

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.